Skip to main content

Table 1 Baseline patient characteristics (n = 176)

From: Prevalence and clinical implications of bronchiectasis in patients with overlapping asthma and chronic rhinosinusitis: a single-center prospective study

Characteristics

Values

Male sex, n (%)

89 (50.57)

Age, y

53.90 ± 14.26 (51.78–56.03)

BMI, kg/m2

24.56 ± 3.94 (23.98–25.15)

Positive smoking statusa, n (%)

55 (31.25)

Smoking indexb, pack-years

10.00 (8.00,14.00)

Duration of asthma, y

6.50 (2.00,18.00)

NPs, n (%)

82 (46.59)

Prior sinus surgery, n (%)

34 (19.32)

Allergic rhinitis, n (%)

112 (63.64)

Atopic dermatitis, n (%)

14 (7.95)

Gastroesophageal reflux disease, n (%)

14 (7.95)

ICS dose (fluticasone equivalent), μg/d

320.00 (160.00, 320.00)

Severe asthma, n (%)

26 (14.77)

≥ 1 severe exacerbation of asthma in the last 12 months, n (%)

54 (30.68)

≥ 1 pneumonia in the last 12 months, n (%)

51 (28.98)

Peripheral blood eosinophil counts, × 109/L

0.37 (0.20,0.70)

FeNO, ppb

36.50 (18.00, 66.00)

Total IgE, IU/mL

177.00 (48.83, 356.50)

Atopy, n (%)

91 (51.70)

Postbronchodilator FEV1% predicted, %

79.10 ± 19.91 (76.13–82.06)

LM scores

10.00 (6.00, 17.00)

Bronchiectasis in HRCT, n (%)

72 (40.91)

  1. Parametric data are expressed as the mean ± SD (95% CI); nonparametric data are expressed as the median (interquartile range). ICS, inhaled corticosteroid; 2 μg beclomethasone = 2 μg budesonide = 1 μg fluticasone
  2. BMI body mass index, NPs nasal polyps, FEV1 forced expiratory volume in 1 s, FeNO fractional exhaled nitric oxide, IgE immunoglobulin E, LM Lund-Mackay
  3. aPositive smoking status included ex- or current-smokers
  4. bSmoking history in patients with positive smoking status